$1.77
5.85% today
Nasdaq, Apr 04, 09:16 pm CET
ISIN
US00972D1054
Symbol
AKBA
Sector
Industry

Akebia Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Akebia Therapeutics, Inc. Classifications & Recommendation:

Buy
100%

Akebia Therapeutics, Inc. Price Target

Target Price $7.38
Price $1.88
Potential
Number of Estimates 4
4 Analysts have issued a price target Akebia Therapeutics, Inc. 2026 . The average Akebia Therapeutics, Inc. target price is $7.38. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 4 analysts: 4 Analysts recommend Akebia Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Akebia Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Akebia Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 160.18 192.37
17.70% 20.10%
Net Margin -46.32% -22.50%
43.20% 51.43%

4 Analysts have issued a sales forecast Akebia Therapeutics, Inc. 2025 . The average Akebia Therapeutics, Inc. sales estimate is

$192m
Unlock
. This is
20.10% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$224m 40.13%
Unlock
, the lowest is
$177m 10.44%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $160m 17.70%
2025
$192m 20.10%
Unlock
2026
$276m 43.23%
Unlock
2027
$364m 32.29%
Unlock
2028
$556m 52.44%
Unlock
2029
$934m 68.07%
Unlock

4 Akebia Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Akebia Therapeutics, Inc. net profit estimate is

$-43.3m
Unlock
. This is
41.67% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-13.5m 81.82%
Unlock
, the lowest is
$-81.0m 9.10%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-74.2m 17.86%
2025
$-43.3m 41.67%
Unlock
2026
$-10.5m 75.76%
Unlock
2027
$25.5m 342.90%
Unlock
2028
$156m 513.30%
Unlock
2029
$461m 194.96%
Unlock

Net Margin

2024 -46.32% 43.20%
2025
-22.50% 51.43%
Unlock
2026
-3.81% 83.07%
Unlock
2027
6.99% 283.46%
Unlock
2028
28.12% 302.29%
Unlock
2029
49.36% 75.53%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.33 -0.19
17.86% 42.42%
P/E negative
EV/Sales 3.30

4 Analysts have issued a Akebia Therapeutics, Inc. forecast for earnings per share. The average Akebia Therapeutics, Inc. EPS is

$-0.19
Unlock
. This is
42.42% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.06 81.82%
Unlock
, the lowest is
$-0.36 9.09%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.33 17.86%
2025
$-0.19 42.42%
Unlock
2026
$-0.05 73.68%
Unlock
2027
$0.11 320.00%
Unlock
2028
$0.70 536.36%
Unlock
2029
$2.05 192.86%
Unlock

P/E ratio

Current -5.73 13.70%
2025
-9.77 70.51%
Unlock
2026
-40.29 312.38%
Unlock
2027
16.59 141.18%
Unlock
2028
2.71 83.66%
Unlock
2029
0.92 66.05%
Unlock

Based on analysts' sales estimates for 2025, the Akebia Therapeutics, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.96 73.68%
2025
3.30 16.79%
Unlock
2026
2.30 30.18%
Unlock
2027
1.74 24.41%
Unlock
2028
1.14 34.40%
Unlock
2029
0.68 40.50%
Unlock

P/S ratio

Current 3.07 55.84%
2025
2.55 16.74%
Unlock
2026
1.78 30.18%
Unlock
2027
1.35 24.41%
Unlock
2028
0.88 34.40%
Unlock
2029
0.53 40.50%
Unlock

Current Akebia Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Jefferies
Locked
Locked
Locked Apr 01 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 14 2025
Piper Sandler
Locked
Locked
Locked Mar 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 23 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Oct 23 2024
HC Wainwright & Co.
Locked
Locked
Locked Oct 10 2024
Analyst Rating Date
Locked
Jefferies:
Locked
Locked
Apr 01 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 14 2025
Locked
Piper Sandler:
Locked
Locked
Mar 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 23 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Oct 23 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Oct 10 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today